Healthcare

The Global Immuno-oncology Therapeutics Market—Checkpoint Inhibitors

The Next Generation of Cancer Therapies

INDUSTRY
Healthcare

RELEASE DATE
04-Jul-2016
REGION
North America
DELIVERABLE TYPE
Market Research

RESEARCH CODE
MBA0-01-00-00-00
SKU
HC02672-NA-MR_18851
Yes
SHARE

The Global Immuno-oncology Therapeutics Market—Checkpoint Inhibitors
Published on: 04-Jul-2016 | SKU: HC02672-NA-MR_18851

Need more details?

$8,000.00

$6,000.00 save 25 %

DownloadLink
Need more details?

Immuno-oncology is based on the premise that tumors escape detection by the immune system, contributing to their growth and progression. Checkpoint inhibitor pathways act as the checks and balances that allow T-cells to recognize foreign substances or tumors. This global study looks at the immune-oncology therapeutics pipeline for checkpoint inhibitors in the drug classes CTLA-4, PD-1/PD-L1, LAG-3, and TIM-3, identifying companies and products in development, dollars spent at each phase (preclinical through launch), cost and reimbursement implications to payers, challenges to commercialization, and opportunities for pharmaceutical, biotech, or diagnostic companies as oncology treatment algorithms evolve. The study period is 2011 to 2020.

Scope and Segmentation

Key Questions this Study will Answer

Key Takeaways

Market Snapshot

Market Snapshot (continued)

8 Big Market Themes for Checkpoint Inhibitors

A Vibrant Ecosystem

Paradigm Expansion to Solid Tumor Cancer Therapies

Regional Launch Highlights

Game-changing Companies

Significant Investor Funding

Key 2016 Predictions—Checkpoint Inhibitor Market

Key Methodology and Scope

Checkpoint Inhibitor Drug Classes

Timeline of Checkpoint Product Approvals

Competitive Landscape—Target Segments, Count of Marketed and Pipeline Products

Checkpoint Segmentation by Subtype

Competitive Landscape—Target Product Counts by Phase

Checkpoint Pipelines by Company, Target, and Phase

Checkpoint Pipelines by Company, Target, and Phase (continued)

Checkpoint Pipelines by Company, Target, and Phase (continued)

Checkpoint Pipelines by Company, Target, and Phase (continued)

Checkpoint Target Segmentation

Competitive Landscape—CTLA-4/CAIX/GITR Segment, Products in Development

Competitive Landscape—PD-1/PD-L1 (programmed death 1-receptor)

Competitive Landscape—LAG-3 (lymphocyte activating gene 3)

Competitive Landscape—TIM-3 (T-cell immunoglobin and mucin domain 3)

PD-1 Product Dashboard—Keytruda® (Pembrolizumab): Merck & Co. (Marketed)

PD-1 Product Dashboard—Opdivo® (Nivolumab): Bristol-Myers Squibb/Ono (Marketed)

CTLA-4 Product Dashboard—Yervoy® (ipilimumab): Bristol-Myers Squibb (Marketed)

PD-L1 Product Dashboard—Tecentriq® (Atezolizumab): Roche (Marketed)

Competitive Overview of Established Companies

Checkpoint Inhibitors—PD-1/PD-L1

PD-L1 Product Dashboard—Avelumab (MSB0010718C): Merck KGaA (Phase III)

PD-L1 Product Dashboard—Durvalumab (MEDI-4736): AstraZeneca / MedImmune (Phase III)

Checkpoint Inhibitors—CTLA-4

CTLA-4 Product Dashboard—Tremelimumab (MEDI-1123): AstraZeneca (Phase III)

Immuno-oncology Combination Therapies

Checkpoint Combination Clinical Trials by Indication

Immuno-oncology Checkpoint Phase III Trials to Watch

Immuno-oncology Checkpoint Phase III Trials To Watch (continued)

Disruptive Technologies and Advances in this Field

Market Opportunities

Potential Game-changing Therapies

Overall Environmental Impact Factors

Checkpoint Product Patent Expirations

Biomarker Challenges

Opportunities in this Market—Escalating Drug Costs

Checkpoint Inhibitor Payer Environment

J-Codes, Annual Costs, and US Payers

Reimbursement Pathway—On-label Reimbursement Path

Reimbursement Pathway—Off-Label, Medicare

Reimbursement Pathway—Off-Label, Commercial Payers

Reimbursement Pathway—Off-Label, Commercial Payers (continued)

A Snapshot of Global Drug Price Control Methods

Pitfalls to Avoid

Companies to Watch

Companies to Watch (continued)

Checkpoint Inhibitor Forecast Sales Total—2020 ($20.5B)Actual Sales by Product

Investors Pour in Significant Funds

Checkpoint Milestones

2015 Deal and Financing—CTLA-4 Receptor Gene Therapy

2015 Deal and Financing Summary—PD-1/PD-L1

2015 Deal and Financing Summary—PD-1/PD-L1 (continued)

2015 Deal and Financing Summary—PD-1/PD-L1 (continued)

2015 Deal and Financing Summary—PD-1/PD-L1 (continued)

2015 Deal and Financing Summary—PD-1/PD-L1 (continued)

2015 Deal and Financing Summary—PD-1/PD-L1 (continued)

2015 Deal and Financing Summary—PD-1/PD-L1 (continued)

2015 Deal and Financing Summary—LAG-3

2015 Deal and Financing Summary—LAG-3 (continued)

2015 Deal and Financing Summary—LAG-3 (continued)

2015 Deal and Financing Summary—TIM-3

Key Conclusions

Growth Opportunities in 4 Checkpoint Inhibitor Segments

New Market Opportunities—Checkpoint Inhibitors

The Last Word—3 Big Predictions

Legal Disclaimer

Pipeline Analysis—CTLA-4/CAIX/GITR Segment, Products in Development

Pipeline Analysis—CTLA-4/CAIX/GITR Segment, Products in Development (continued)

Pipeline Analysis—CTLA-4/CAIX/GITR Segment, Products in Development (continued)

Pipeline Analysis—CTLA-4/CAIX/GITR Segment, Products in Development (continued)

Pipeline Analysis—CTLA-4/CAIX/GITR Segment, Products in Development (continued)

Pipeline Analysis—LAG-3 Products in Development

Pipeline Analysis—LAG-3 Products in Development (continued)

Pipeline Analysis—LAG-3 Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)

Pipeline Analysis—TIM-3 (T-cell immunoglobin and mucin domain 3) Segment, Products in Development

Pipeline Analysis—TIM-3 (T-cell immunoglobin and mucin domain 3) Segment, Products in Development (continued)

Pipeline Analysis—TIM-3 (T-cell immunoglobin and mucin domain 3) Segment, Products in Development (continued)

The Frost & Sullivan Story

Value Proposition: Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence


Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Healthcare research

16 Nov 2026   |   North America   |   Frost Radar

Frost Radar™: Healthcare Data Interoperability Platforms and Integration Engines in North America, 2026

This Frost Radar™ analyzes the healthcare data platform and integration engine vendors that enable healthcare organization to improve the exchange, utilization, contextualization, and management of clinical, operational, financial, and administrative data. Data issues, AI adoption, and solution gove...

03 Nov 2026   |   North America   |   Market Research

Enterprise Imaging Market, United States, 2025–2030

Enterprise imaging is no longer a technology upgrade. It is becoming the operating model for imaging across the provider organization, and the next investment cycle will decide which vendors lead it. This study gives vendors, ecosystem partners, and provider leaders a 360-degree view of that shift, ...

02 Nov 2026   |   Global   |   Market Research

Continuous Glucose Monitoring Market, Global, 2026

The global continuous glucose monitoring (CGM) market is undergoing a fundamental transformation as the technology evolves from a prescription-led glucose monitoring device into an AI-connected metabolic intelligence ecosystem. Market expansion is increasingly driven by the emergence of over-the-cou...

28 Oct 2026   |   Global   |   Frost Radar

Frost Radar™: Health Monitoring Wearable Solutions, 2026

The health monitoring wearables industry is undergoing a profound transformation as competitive advantage shifts from device hardware to integrated digital health ecosystems. Market leaders are differentiating through clinically validated health insights, longitudinal data platforms, AI-enabled anal...

26 Oct 2026   |   Global   |   Technology Research

Game-Changing Innovations Transforming Cardiovascular Care

The study analyzes game-changing technologies transforming cardiovascular care across diagnosis, image-guided intervention, functional assessment, clinical workflow, and longitudinal patient monitoring. The analysis covers five segments: diagnostic imaging and AI-enabled cardiac assessment; interve...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.